Humanwell Healthcare (600079.SH) announced that its subsidiary Yichang Humanwell Pharmaceutical Co., Ltd. (holding 80% equity) has registered the Phase II clinical trial information for HW231019 tablets on the National Medical Products Administration's drug clinical trial registration platform. The trial objectives include: 1) evaluating the efficacy and safety of HW231019 tablets for postoperative abdominal pain relief, and 2) preliminary exploration of dosage and administration for postoperative analgesia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments